THE SCOPE OF THIS TASK ORDER IS (1). PRODUCTION OF A DRUG SUBSTANCE, (2) CONVERSION OF DRUG SUBSTANCE TO DRUG PRODUCT, (3) FILLING DRUG PRODUCT INTO APPLICATORS TO BE USED IN THE CLINICAL TRIALS, AND

NIH RePORTER · NIH · N02 · $1,866,116 · view on reporter.nih.gov ↗

Abstract

The clinical product being produced under this task order is a biotherapeutic drug product. The product to be produced under this task order is a live biotherapeutic, Lactobacillus crispatus to be used for correcting microflora in women with bacterial vaginosis and vaginal dysbiosis. This results in a vaginal microbiota dominated with lactobacillus which helps in lowering risk of cervical dysplasia and cancer.

Key facts

NIH application ID: 11219071
Project number: 75N91023D00010-0-759102400001-1
Recipient: MIDWEST RESEARCH INSTITUTE
Principal Investigator: JON WHITE
Activity code: N02
Funding institute: NIH
Fiscal year: 2024
Award amount: $1,866,116
Award type: —
Project period: 2024-09-18 → 2026-09-17